Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

Kathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.

Replacing June Halper: What's Next for CMSC

Articles

While effective in reducing amyloid plaques, donanemab carries a notable risk of amyloid-related imaging abnormalities (ARIA), underscoring the need for careful patient monitoring and risk management strategies.

Insights From the TRAILBLAZER-ALZ Program: Elevated ARIA Risk with Donanemab Highlights the Need for Vigilant Monitoring

Findings from a recently published large-scale analysis highlighted the high burden of cognitive impairment among veterans with both migraine and TBI. 

Veteran Analysis Reveals Significant Cognitive Symptoms Stemming From Migraine and Traumatic Brain Injury

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

What to Expect From the 2025 CMSC Annual Meeting: Kathleen Costello, CRNP, MSCN

Interim chief executive officer of the Consortium of Multiple Sclerosis Centers.

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody-associated disease. [WATCH TIME: 3 minutes]

Challenges and Research Priorities for Pediatric MOGAD: Kelsey Poisson, MD

, has been with the team since September 2022. Follow her on Twitter 

The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.

NeuroVoices: Tanya Simuni, MD, FAAN, on Using the Neuronal α-Synuclein Disease Integrated Staging System Framework to Advance Parkinson Disease Staging

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

ISC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Slideshows

New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.

Clinical

Antibody Testing in Patients With Neurological and Psychiatric Symptoms